Myriad Genetics, Inc.

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-21 pm EST			5-day change	1st Jan Change
5.840 ^USD	+2.82%		-4.42%	-5.04%

Jan. 14	Myriad Genetics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 05:15 PM
Jan. 12	Myriad Genetics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025 and 2026	CI

Myriad Genetics Collaborates With Clairity, MagView to Roll Out AI Platform for Breast Cancer Risk Assessment

Published on 11/25/2025 at 06:21 pm EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Myriad Genetics, Inc.

Jan. 14	Myriad Genetics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 05:15 PM
Jan. 12	Myriad Genetics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025 and 2026	CI
Jan. 12	Myriad Genetics announces select preliminary fourth quarter and full year 2025 financial results and introduces full year 2026 financial guidance	RE
Dec. 19	Indian Equities Rebound on Friday as Rupee Stability Lifts Sentiment	MT
Dec. 19	Zydus Lifesciences Signs Pact to Launch Cancer-Risk Assessment Diagnostic Tests in India	MT
Dec. 18	Zydus Lifesciences signs agreement with Myriad Genetics for cancer-risk tests in India	RE
Dec. 18	Zydus Lifesciences Limited Signs an Exclusive Agreement with Myriad Genetics	CI
Nov. 26	Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	MT
Nov. 25	Myriad Genetics Collaborates With Clairity, MagView to Roll Out AI Platform for Breast Cancer Risk Assessment	MT
Nov. 25	Clairity, Myriad Genetics, Inc. and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health	CI
Nov. 10	Myriad Genetics Expands Cancer Test With Additional Actionable Genes From NCCN Guidelines	MT
Nov. 10	Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk®? Hereditary Cancer Test to Support Evolving Clinical Needs	CI
Nov. 06	Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference	CI
Nov. 04	UBS Adjusts Myriad Genetics Price Target to $8 From $6, Maintains Neutral Rating	MT
Nov. 03	Myriad Genetics, Inc., Q3 2025 Earnings Call, Nov 03, 2025
Nov. 03	Myriad Genetics Q3 revenue beats on volume growth in hereditary cancer testing	RE
Nov. 03	Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full-Year 2025	CI
Nov. 03	Myriad Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-31	Myriad Genetics, Inc. Announces A Post-Hoc Analysis of the Precision Medicine in Mental Health Care Study	CI
25-10-30	Neogen® Corporation Announces the Appointment of Bryan Riggsbee as Its Senior Vice President, Effective November 3, 2025	CI
25-10-30	Neogen® Corporation Announces the Appointment of Bryan Riggsbee as Chief Financial Officer, Effective November 3, 2025	CI
25-10-15	Kringle Pharma Establishes US Subsidiary to Accelerate Spinal Cord Injury Program	MT
25-10-14	Myriad Genetics, Inc. Adds F8, FXN Genes to Foresight Universal Plus Panel	CI
25-10-03	Myriad Genetics, Inc. Announces Executive Changes, Effective October 24, 2025	CI
25-10-01	Revance Appoints Scott Leffler as Chief Financial Officer, Effective October 1, 2025	CI

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.

Employees

2,700

Sector

Medical Equipment, Supplies & Distribution

Calendar

Mar. 02 - Q4 2025 Earnings Release (Projected)

More about the company